Porphyrin

Keio University Research: Family of ring-like molecules grows

Retrieved on: 
Thursday, March 14, 2024
Absorption, Human body, Nitrogen, Zinc, Fluorescence, Light, Copper, Metal, Research, Porphyrin, Carbon, Plant, TEQ, Keio University, Oxygen, Photosynthesis

Now, two such ring-like molecules have been successfully synthesized, with possible applications including sensors and catalysts.

Key Points: 
  • Now, two such ring-like molecules have been successfully synthesized, with possible applications including sensors and catalysts.
  • Cyclic compounds are molecules in which some of the atoms are connected to form a closed ring.
  • Given their key roles in living organisms, porphyrins have inspired the design of synthetic compounds for various applications.
  • Recently, Naoya Kumagai from Keio University and colleagues have succeeded in synthesizing two new members of the porphyrin family, with promising physicochemical properties such as fluorescence and catalytic activity.

Keio University Research: Family of ring-like molecules grows

Retrieved on: 
Thursday, March 14, 2024
Absorption, Human body, Nitrogen, Zinc, Fluorescence, Light, Copper, Metal, Research, Porphyrin, Carbon, Plant, TEQ, Keio University, Oxygen, Photosynthesis

Now, two such ring-like molecules have been successfully synthesized, with possible applications including sensors and catalysts.

Key Points: 
  • Now, two such ring-like molecules have been successfully synthesized, with possible applications including sensors and catalysts.
  • Cyclic compounds are molecules in which some of the atoms are connected to form a closed ring.
  • Given their key roles in living organisms, porphyrins have inspired the design of synthetic compounds for various applications.
  • Recently, Naoya Kumagai from Keio University and colleagues have succeeded in synthesizing two new members of the porphyrin family, with promising physicochemical properties such as fluorescence and catalytic activity.

bioAffinity Technologies In The News

Retrieved on: 
Tuesday, January 30, 2024
Technology, Surgery, Medical Devices, General Health, Science, Genetics, Clinical Trials, FDA, Biotechnology, Health, Health Technology, Research, Software, Other Health, Radiology, Pharmaceutical, Oncology, Intelligence, Lung cancer, College, Therapy, Clinical Laboratory, Sputum, CLIA, BIAF, Laboratory, Artificial intelligence, TCPP, Patent, Lung, Accreditation, CAP, Porphyrin, Cancer, Malignancy, Medical imaging

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
  • Precision Pathology Laboratory Services (PPLS), a bioAffinity Technologies company, successfully passed the rigorous biannual inspection required for College of American Pathologists (CAP) accreditation.
  • ScienceSoft , which provides IT consulting and software development services to more than 1,200 clients around the globe, recently published a case study of its work with bioAffinity Technologies.
  • More than 1,000 people registered for Webull Corporate Connect’s recent investment webinar that featured bioAffinity Technologies ’ President and CEO Maria Zannes and two other healthcare executives.

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

Retrieved on: 
Tuesday, January 23, 2024
Technology, Surgery, Medical Devices, Science, Genetics, Clinical Trials, FDA, Biotechnology, Health, Health Technology, Research, Other Technology, Other Health, Radiology, Pharmaceutical, Artificial Intelligence, Oncology, Patient, Therapy, Compound, Intelligence, Malignancy, Cancer, Lung cancer, Porphyrin, Disease, Controller, Grant, Physician, Treating, BIAF, Lung, Pharmaceutical industry

The Indian patent, titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” is an important addition to bioAffinity Technologies’ patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics.

Key Points: 
  • The Indian patent, titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” is an important addition to bioAffinity Technologies’ patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics.
  • “India’s patent is an acknowledgement of the value of our ongoing research, development and commercialization of porphyrin-based diagnostics and targeted treatments for lung cancer and other diseases,” bioAffinity Technologies’ President and CEO Maria Zannes said.
  • “We are committed to improving the outcome for cancer patients around the world, beginning with lung cancer, the deadliest cancer killer.
  • Physicians use CyPath® Lung for patients at high risk for developing lung cancer, often after recommended screening reveals indeterminate pulmonary lung nodules that may or may not be malignant.

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Diarrhea, Marketing, Diabetes, INN, Diabetic ketoacidosis, Allergy, ATC, International, Pancreas, Insulin, Disease, Language, Blood, Porphyrin, Mellitus, Glycated hemoglobin, Mouth, Blood sugar level, Infant, Abdominal pain, Porphyria, KATP, European Medicines Agency, ATP, Tablet, Chronic pain, Select, Cell, Patient, Time, Anatomy, Medicine, IIA, Neonatal diabetes, Hypoglycemia, Life, Medical device

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

BioMimetix Presents Data from Phase 2 Study of BMX-001 Demonstrating Increased Survival of 6.6 Months in High Grade Glioma Patients at the 2023 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Friday, November 17, 2023
Oncology, Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Temozolomide, Annual general meeting, Radiation, Porphyrin, Pakistan Society of Neuro-Oncology, HGG, Disease, Patient, TMZ, White matter, Neuro-Oncology (journal), Prognosis, Standard of care, MD, RT, Cancer, Survival, Toxic leukoencephalopathy, Growth, Neoplasm, Quality of life, SNO, Lead, Medical imaging, Cognition

“Patients with high grade glioma are challenging to treat because the disease grows quickly, ultimately outcomes are very poor for these patients and often carries an unfavorable prognosis.

Key Points: 
  • “Patients with high grade glioma are challenging to treat because the disease grows quickly, ultimately outcomes are very poor for these patients and often carries an unfavorable prognosis.
  • This is demonstrated by the promising effects seen in this trial with BMX-001 on patients with high grade glioma receiving concurrent radiation and chemotherapies,” said James Crapo, M.D., Chief Executive Officer at BioMimetix.
  • “High grade glioma is an aggressive brain cancer with a low survival rate that affects 10,000-15,000 people in the US per year.
  • Patients on concurrent RT/TMZ who also received BMX-001 were found to have an increased median survival of 6.6 months.

BioMimetix Announces Acceptance of Late-Breaking Abstract and Oral Presentation of BMX-001 Clinical Data at the 2023 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Thursday, October 26, 2023
Oncology, Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Porphyrin, HGG, Pakistan Society of Neuro-Oncology, SNO, Cancer, Patient, Annual general meeting, Pharmaceutical industry

BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced that data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG), has been selected as a late breaking oral presentation at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting taking place on November 15-19, 2023 in Vancouver, Canada.

Key Points: 
  • BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced that data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG), has been selected as a late breaking oral presentation at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting taking place on November 15-19, 2023 in Vancouver, Canada.
  • In line with conference publication guidelines, Late-Breaking Abstracts will be made public at 7:00 a.m. PT on the first day of the meeting, Friday, November 17, 2023 and at https://academic.oup.com/neuro-oncology/supplements .
  • Details of the oral presentation are as follows:
    Date and Time: Friday, November 17, 2023, from 9:05 – 9:15 a.m. PT

bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Friday, March 31, 2023
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Clinical Trials, Other Health, Sputum, COPD, Survival rate, Exercise, IPO, LDT, American Lung Association, Physician, Communication, Survival, Food and Drug Administration, Respiratory Research, Cancer, Lung cancer, Receiver operating characteristic, Medicine, BIAF, Lung, Sale, Chronic obstructive pulmonary disease, Patient, Patent, Machine learning, Flow cytometry, Laboratory developed test, United Kingdom, Diagnosis, Porphyrin, Therapy, National Board of Medical Examiners, Food, Biopsy, Medical imaging, Security (finance), Pharmaceutical industry, Video game, Cryptocurrency, ROC

Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.
  • Research and development expenses were $429,000 for the fourth quarter of 2022, compared with $318,000 for the comparable period in 2021.
  • General and administrative expenses were $1.2 million for the fourth quarter of 2022, compared with $341,000 for the comparable period in 2021.
  • bioAffinity Technologies believes that its available cash will be sufficient to fund planned operations for at least the next 12 months.

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments

Retrieved on: 
Wednesday, January 4, 2023
Research, General Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Science, Surgery, Biotechnology, Health, TCPP, Porphyrin, Therapy, Patent, BIAF, Research, Patient, European Patent Convention, Treating, Quality of life, European Patent Office, Survival, Lung, Pharmaceutical industry, Cancer

(NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” for the targeted delivery of novel cancer treatments.

Key Points: 
  • (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” for the targeted delivery of novel cancer treatments.
  • A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted for the claimed invention.
  • The U.S. patent will issue to the Company’s wholly owned subsidiary OncoSelect and grant protection to 2037.
  • New treatments delivered by more specific targeting agents like porphyrins are needed to improve survival and a survivor’s quality of life.

bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia

Retrieved on: 
Tuesday, October 25, 2022
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Clinical Trials, Other Health, Physician, Lung, Time, Disease, Sale, Laboratory developed test, Laboratory, LLC, NASDAQ, LDT, Research, Compound, Cancer, Lung cancer, Company, Treating, BIAF, Porphyrin, Flow cytometry, Â, United Kingdom, Forward-looking statement, University, University of Texas Southwestern Medical Center, Death, Pharmaceutical industry, Medical imaging, Patent

bioAffinity Technologies also announced that Mexico and Australia recently awarded the Company therapeutic patents with claims directed to novel compounds of porphyrin conjugates for selective delivery of cancer treatment.

Key Points: 
  • bioAffinity Technologies also announced that Mexico and Australia recently awarded the Company therapeutic patents with claims directed to novel compounds of porphyrin conjugates for selective delivery of cancer treatment.
  • Cancer is the leading cause of death in China, said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies.
  • The award of these patents in China, Mexico and Australia is further evidence that bioAffinity Technologies can be a leader in advancing novel approaches for both diagnosing and treating this deadliest of diseases.
  • The Company and its subsidiary OncoSelect hold patents in the U.S., Australia, Canada, China, France, Germany, Hong Kong, Italy, Mexico, Spain, Sweden, and the United Kingdom.